Tel Aviv Stock Exchange Ltd. · TASE:TASE
Tel Aviv Stock Exchange — Novolog Group — Q1 2023 Earnings Presentation
27 slides from Tel Aviv Stock Exchange's earnings presentation, May 29, 2023
Slide 1: Q1-2023 Results
May 29, 2023 Q1-2023 Results Novolog Group
Slide 2: Forward Looking Statement
Forward Looking Statement The presentation does not constitute a recommendation, advice, opinion or an Company’s business and macroeconomic facts and figures, all as known to the offer to acquire securities of Novolog (Pharm Up 1966) Ltd (the “Company”), or an Company at the time of preparation of t
Slide 3: Company Profile
Company Profile Delivering Health Founded in 1966 Listed on the Tel-Aviv Stock Exchange in 2017 (TA125) Major stakeholders: Udi Puzis, Mori Arkin, Eli Novolog operates to improve the field of Dahan and institutional healthcare in Israel and adapt it to the investors challenges of the future through
Slide 4: Creating the future of healthcare
Our Vision is Based on Our Values Creating the future of healthcare The Novolog Group is committed to be a leading healthcare services group in Israel and to support patients, physicians and healthcare organizations in Israel and internationally through our innovative, advanced, technology-based bas
Slide 5: Well-defined Strategy to Drive Growth
Strategic Goals Well-defined Strategy to Drive Growth Operate complex and Reduce public healthcare Improve the public’s Provide physicians and supplementary logistics organizations’ costs, access to high-quality, patients with the services for medicines, thereby helping them innovative, and advanced
Slide 6: Group Structure
Group Structure Complex logistics services High quality medical care Medical information technological including import and distribution of based on innovation, tools, and digital services to pharmaceuticals and medical compassion, and personalized patients, physicians, and medical devices, as well
Slide 7: Y) ) a i) 02) i. ep) fe) a Dn fo} =| fo} >
Y) ) a i) 02) i. ep) fe) a Dn fo} =| fo} > fe} = > a a
Slide 8: Senior Strategic Logistics Partner of Global Pharma and Medical Device Companies
Logistics Division Senior Strategic Logistics Partner of Global Pharma and Medical Device companies Novolog group is a senior strategic logistics partner of global pharma companies operating in Israel. Novolog uses state-of- the-art technologies to operate a variety of services for these companies,
Slide 9: Logistics Division Services
Logistics Division Services Pharma logistic services Specializes in storage, distribution and logistic services for the pharmaceutical, Medical Device and narcotics industries and operates a state-of-the-art logistics center Clinical trial logistical services While adhering to the strictest quality
Slide 10: Healthcare by Novolog
° Healthcare by Novolog
Slide 11: Healthcare Division: Improving Quality of Care
Healthcare Division Improving Quality of Care Hundreds of patients intubated at home Novolog’s Healthcare Division works with Hundreds hospitals, leading insurance providers, of home medical visits per pharmaceutical companies, and all of the month Israeli national HMOs to provide technology- Millio
Slide 12: Improving Healthcare Access and Convenience
Healthcare Division Services Improving Healthcare Access and Convenience Home Care Services Healthcare Management National Healthcare Projects At-home hospitalization, Building and operating Partnerships with national ambulatory homecare, customized management organizations providing respiratory car
Slide 13: Making Healthcare Personal
Healthcare Division Services Making Healthcare Personal Personalized Concierge Medicine Established Israel’s first personalized healthcare management center, providing comprehensive testing and expert treatment services in clinics and in patients’ homes., as well as operating Israel’s largest privat
Slide 14: Digital Health by Novolog
6! DigitalHealth by Novolog
Slide 15: Digital Health Division: Enabling Patient Access
Digital Health Division Enabling Patient Access Novolog’s digital health division is providing patients with unprecedented access to treatment information, scheduling, and communication with care providers, giving them newfound control over their therapeutic process and their Millions interactions w
Slide 16: Technological Tools Suitable for the New Era of Healthcare Services
Digital Health Division Services Technological Tools Suitable for the New Era of Healthcare Services Smart Scheduling platform Telemedicine platform Medical content platforms Enhance chronic disease treatment • Enables patient • Video consultations • Healthcare provider reviews • Support patients in
Slide 17: Financial Overview Q1-2023
Financial Overview Q1-2023 Q1-2023 Results | May 29, 2023 17
Slide 18: Significant business developments
Significant business developments • In the first quarter of 2023, the company recorded a provision of NIS 23.2 million for the impairment of its holding in Medflex. As of March 31, 2023 the balance of the investment in Medflex is NIS 7 million. The investment in Medflex has no impact on the company'
Slide 19: Q1-2023 Results Including IFRS16
Q1-2023 Results Including IFRS16 (NIS millions) Q1-2023 Q1-2022 % Change GROSS PROFIT Revenues 413.2 375.4 10.1% +10% Gross Profit 47.5 43.2 9.8% OPERATING PROFIT Operating Profit 21.6 20.4 5.5% +5% Profit after taxes (*) 15.8 13.8 14.5% ADJUSTED EBITDA Net Profit (loss) )8.8( 13.0 - +0.2% Adjusted
Slide 20: Q1-2023 Results Excluding IFRS16
Q1-2023 Results Excluding IFRS16 (NIS millions) Q1-2023 Q1-2022 % Change GROSS PROFIT Revenues 413.2 375.4 10.1% +9% Gross Profit 47.0 43.0 9.2% OPERATING PROFIT Operating Profit 20.6 19.6 5.0% +5% Profit after taxes (*) 16.8 14.7 14.1% ADJUSTED EBITDA Net Profit (loss) )7.8( 13.9 - -3% Adjusted EBI
Slide 21: Q1-2023 Results By Segment Excluding IFRS16
Q1-2023 Results By Segment Excluding IFRS16 (NIS millions) Revenues Adjusted EBITDA Q1-2023 Q1-2022 % Q1-2023 Q1-2022 % Logistics (*) 352.3 308.1 14.4% 18.5 17.6 5.0% Health Care (**) (***) 55.3 60.8 )9.1%( 7.0 9.0 (21.7%) Digital Health 6.6 6.9 )3.7%( 2.4 2.2 7.4% Intercompany )1.0( )0.4( - - Trans
Slide 22: Q1-2023 Balance Sheet Including IFRS16
Q1-2023 Balance Sheet Including IFRS16 (NIS millions) 31/03/2023 31/12/2022 Cash 172 173 CASH Current assets 1,846 1,719 NIS 172M Non-current assets 701 716 EQUITY Current liabilities 1,903 1,757 NIS 439M Non-current liabilities 205 216 DEBT Equity 439 462 2,547 2,435 NIS 1.8M Total assets Q1-2023 R
Slide 23: Growth Engines
Growth Engines Expanding Developing Adding more personalized additional home services for the healthcare care services for pharmaceutical services the institutional industry market Entering new Entering new Leverage Digital market segments international Health Division markets Services Q1-2023 Resul
Slide 24: Long Term Guidance
Long Term Guidance Uniquely Positioned To Deliver Value To Stakeholders As part of our long-range growth plan, we estimate that Novolog will double its Adjusted EBITDA (Excluding IFRS16) with respect to 2021, within 4 years, mainly from its activities in Israel Q1-2023 Results | May 29, 2023 24
Slide 25: Financial Executive Summary
Financial Executive Summary Strong financial Diversification Responsible approach Capital allocation performance priorities Novolog has a consistent Future growth will be The Company is not Investing for continued track record of delivering fueled by all three leveraged and invests growth and maximi
Slide 26: Capital Allocation Strategy for Growth
Capital Allocation Strategy for Growth Reinvest for growth Acquisitions Returns to our shareholders Investing in processes and Acquisitions that support our Dividend policy – ventures that lead to organic strategies 70% of the net profit growth and generate higher profits Q1-2023 Results | May 29, 2
Slide 27: Thank you!
Thank you! info@Novolog.co.il | www.Novolog.co.il